(A) Genome-wide ribonucleic acid interference screen targeting over 18,000 genes in cultured endothelial cells (ECs), and publicly available genome wide association studies (GWAS) reveal activin-like kinase 1 (ALK1) as an EC-specific low density lipoprotein (LDL)-binding protein responsible for mediating LDL uptake and transcytosis. (B) Proposed mechanism showing that in conditions of hypercholesterolemia, ALK1 binds LDL particles, which are then internalized by ECs via an endocytic pathway that prevents LDL from lysosomal degradation, consequently resulting in enhanced LDL transcytosis. LDLR ¼ low-density lipoprotein receptor; siRNA ¼ small interfering ribonucleic acid. manner that is independent of the LDLR. This was followed by a series of complementary assays, which included total internal reflectance microscopy, to demonstrate that ALK-1 mediates LDL movement from the apical side to the basolateral membrane of the endothelium. Last, in vivo data generated in endothelial-specific ALK1-deficient mice on an LDLR background showed reduced LDL uptake in the aortic
SUMMARY
It is now known that the internalization and transcytosis of low density lipoprotein (LDL) in the vessel wall occurs through molecular pathways independent of the LDL receptor. In a study recently published in Nature Communications, investigators cross-referenced results from a genome-wide ribonucleic acid interference screen with targets identified in publicly-available genome-wide association studies datasets to identify activin-like kinase 1 as a novel driver of this process. This approach has relevance to the field of atherosclerosis, and could be used as a model for the prioritization of 
